Ozbalci Demircan, Alanoglu Emine Guchan, Findos Eda, Eroglu Hande Nur
Suleyman Demirel University Research and Education Hospital, Department of Hematology, Isparta, Turkey.
Suleyman Demirel University Research and Education Hospital, Department of Internal Medicine, Isparta, Turkey.
J Med Biochem. 2023 Mar 15;42(2):274-281. doi: 10.5937/jomb0-39375.
Alterations of plateletcrit and mean platelet volume (MPV) and pathogenesis of chronic lymphocytic leukaemia (CLL) have been linked to various inflammatory disorders. The prognostic impact of plateletcrit and MPV were evaluated.
MPV and plateletcrit levels of both CLL and control group were compared and then in CLL patients, additional diseases, leukocyte count, platelet count, lactate dehydrogenase, Rai stage, progression-free and overall survival, mutations, if any, and chemotherapy, if any, were recorded. Then, the relationship between MPV and plateletcrit values and these parameters were evaluated in CLL patients.
Platelet and plateletcrit values were found to be significantly lower in CLL patients than the control group (p<0.001) for both. Plateletcrit and MPV values of patients who did not receive chemotherapy were higher than those who received chemotherapy (p=0.03, p=0.02, respectively). Being over 75 years old, plateletcrit value less than 0.1565 %, platelet level below 175 x 109/L, and leukocyte count greater than 53.5 x 109/L was found to significantly reduce overall survival. Male gender, each stage increase, plateletcrit less than 0.1565 % and leukocyte count greater than 53.5 x 109/L was related to reduce treatment-free survival in CLL patients.
Plateletcrit can be a viable prognostic marker for defining both treatment free and overall survival.
血小板压积和平均血小板体积（MPV）的改变以及慢性淋巴细胞白血病（CLL）的发病机制与多种炎症性疾病有关。评估了血小板压积和MPV的预后影响。
比较CLL组和对照组的MPV和血小板压积水平，然后记录CLL患者的其他疾病、白细胞计数、血小板计数、乳酸脱氢酶、Rai分期、无进展生存期和总生存期、是否存在突变以及是否接受化疗。然后，评估CLL患者中MPV和血小板压积值与这些参数之间的关系。
发现CLL患者的血小板和血小板压积值均显著低于对照组（两者p<0.001）。未接受化疗的患者的血小板压积和MPV值高于接受化疗的患者（分别为p=0.03，p=0.02）。发现年龄超过75岁、血小板压积值低于0.1565%、血小板水平低于175×10⁹/L以及白细胞计数高于53.5×10⁹/L会显著降低总生存期。男性、分期每增加一期、血小板压积低于0.1565%以及白细胞计数高于53.5×10⁹/L与CLL患者无治疗生存期缩短有关。
血小板压积可以作为定义无治疗生存期和总生存期的可行预后标志物。
